SCHEMBL5269591

SCHEMBL5269591

OC(c1ccccc1)C(NCc1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.55
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CYP2D6 P10635 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
ACP3 P15309 3/20 0.50
KDM4E B2RXH2 1/20 0.49
MAN2A1 Q16706 2/20 0.47
MAN1B1 Q9UKM7 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
SIGMAR1 Q99720 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
THRB P10828 1/20 0.43
IDO1 P14902 1/20 0.43
BCHE P06276 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13191170 1.00 AOC3 (0.55) AOC3ALDH1A1LMNAMAPK1HTT
SCHEMBL5268676 0.90 SMN1; SMN2 (0.54) AOC3ALDH1A1LMNAMAPK1HTT
SCHEMBL5273602 0.90 CYP1A2 (0.62) AOC3ALDH1A1LMNAMAPK1HTT
SCHEMBL5274497 0.86 TDP1 (0.56) ALDH1A1LMNAMAPK1HTTNPSR1
SCHEMBL1305451 0.86 ACP3 (0.53) ALDH1A1LMNAMAPK1HTTNPSR1
SCHEMBL7189369 0.86 ACP3 (0.53) ALDH1A1LMNAMAPK1HTTNPSR1
SCHEMBL14099897 0.86 ACP3 (0.53) ALDH1A1LMNAMAPK1HTTNPSR1
SCHEMBL17314012 0.83 SIGMAR1 (0.52) ALDH1A1LMNAMAPK1HTTNPSR1
SCHEMBL8430372 0.80 ACP3 (0.50) ALDH1A1LMNAMAPK1HTTNPSR1
SCHEMBL9427609 0.80 ACP3 (0.50) ALDH1A1LMNAMAPK1HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111094281-B Chemical process for preparing monolactam antibiotics and intermediates thereof 诺华股份有限公司 2023-08-29 CN disclosed
US-11414411-B2 Chemical process for manufacturing monobactam antibiotic and intermediates thereof NOVARTIS AG (CH) 2022-08-16 US disclosed
EP-3661933-B1 PROCESS FOR PREPARING 1-(((Z)-(1-(2-AMINOTHIAZOL-4-YL)-2-OXO-2-(((3S,4R)-2-OXO-4-((2-OXOOXAZOLIDIN-3-YL)METHYL)-1-SULFOAZETIDIN-3- YL)AMINO)ETHYLIDENE)AMINO)OXY)CYCLOPROPANE CARBOXYLIC ACID NOVARTIS AG (CH) 2022-03-23 EP disclosed
US-20200239461-A1 CHEMICAL PROCESS FOR MANUFACTURING MONOBACTAM ANTIBIOTIC AND INTERMEDIATES THEREOF SUZHOU NOVARTIS PHARMA TECHNOLOGY CO., LTD. (CN) 2020-07-30 US disclosed
CN-111094281-A Chemical process for the preparation of monobactam antibiotics and intermediates thereof 诺华股份有限公司 2020-05-01 CN disclosed
EP-1074539-B1 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL CO (JP) 2007-10-17 EP disclosed
US-6894190-B2 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-17 US disclosed
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2003-12-18 US disclosed
US-6653507-B2 Useful intermediate compound of pharmaceuticals for urinary incontinence SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-11-25 US disclosed
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2002-10-03 US disclosed
US-6403832-B1 MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-06-11 US disclosed
EP-1074539-A2 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414411-B2 Chemical process for manufacturing monobactam antibiotic and intermediates thereof SRR, DCXR, JMJD6 AOC3 1835/4885ALDH1A1 3899/4885LMNA 4393/4885
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, CYP8B1, CYP11B2 AOC3 483/4885ALDH1A1 141/4885LMNA 1166/4885
US-20200239461-A1 CHEMICAL PROCESS FOR MANUFACTURING MONOBACTAM ANTIBIOTIC AND INTERMEDIATES THEREOF SRR, DCXR, JMJD6 AOC3 1835/4885ALDH1A1 3899/4885LMNA 4393/4885
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, ALDH7A1, ALDH18A1 AOC3 169/4885ALDH1A1 73/4885LMNA 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.